AstraZeneca PLC ADR (AZN): Price and Financial Metrics

AstraZeneca PLC ADR (AZN): $67.82

0.40 (-0.59%)

POWR Rating

Component Grades








Add AZN to Watchlist
Sign Up

AZN Price/Volume Stats

Current price $67.82 52-week high $76.56
Prev. close $68.22 52-week low $53.24
Day low $67.80 Volume 753,309
Day high $68.72 Avg. volume 4,837,049
50-day MA $68.79 Dividend yield 1.34%
200-day MA $69.63 Market Cap 210.23B

AZN Stock Price Chart Interactive Chart >


  • AZN scores best on the Growth dimension, with a Growth rank ahead of 89.75% of US stocks.
  • The strongest trend for AZN is in Quality, which has been heading up over the past 177 days.
  • AZN's current lowest rank is in the Momentum metric (where it is better than 9.57% of US stocks).

AZN Stock Summary

  • AZN has a higher market value than 99.21% of US stocks; more precisely, its current market capitalization is $209,873,920,063.
  • AZN's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.07 -- higher than only 1.12% of US-listed equities with positive expected earnings growth.
  • In terms of twelve month growth in earnings before interest and taxes, ASTRAZENECA PLC is reporting a growth rate of 61,911.11%; that's higher than 99.98% of US stocks.
  • If you're looking for stocks that are quantitatively similar to ASTRAZENECA PLC, a group of peers worth examining would be NVS, PFE, NFLX, ABBV, and CSCO.
  • AZN's SEC filings can be seen here. And to visit ASTRAZENECA PLC's official web site, go to

AZN Valuation Summary

  • AZN's price/sales ratio is 5; this is 127.27% higher than that of the median Healthcare stock.
  • Over the past 243 months, AZN's price/earnings ratio has gone up 21.4.

Below are key valuation metrics over time for AZN.

Stock Date P/S P/B P/E EV/EBIT
AZN 2023-06-28 5.0 6.1 46.7 43.9
AZN 2023-06-27 5.1 6.2 47.2 44.3
AZN 2023-06-26 5.1 6.2 47.3 44.4
AZN 2023-06-23 5.1 6.2 47.5 44.6
AZN 2023-06-22 5.2 6.4 48.7 45.6
AZN 2023-06-21 5.2 6.4 48.3 45.3

AZN Growth Metrics

    Its 3 year price growth rate is now at 74.78%.
  • Its 3 year cash and equivalents growth rate is now at 39.31%.
  • The 2 year cash and equivalents growth rate now stands at 68.83%.
Over the past 70 months, AZN's revenue has gone up $22,059,000,000.

The table below shows AZN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 44,351 9,808 3,288
2022-12-31 44,351 9,808 3,288
2022-09-30 45,154 8,828 2,039
2022-06-30 44,038 7,617 -1,253
2022-03-31 41,487 7,261 -1,063
2021-12-31 37,417 5,963 112

AZN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AZN has a Quality Grade of B, ranking ahead of 78.56% of graded US stocks.
  • AZN's asset turnover comes in at 0.438 -- ranking 104th of 681 Pharmaceutical Products stocks.
  • CLVS, HSKA, and FLXN are the stocks whose asset turnover ratios are most correlated with AZN.

The table below shows AZN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.438 0.765 0.209
2021-03-31 0.431 0.792 0.231
2020-12-31 0.429 0.801 0.205
2020-09-30 0.427 0.801 0.174
2020-06-30 0.433 0.800 0.161
2020-03-31 0.422 0.794 0.126

AstraZeneca PLC ADR (AZN) Company Bio

AstraZeneca plc engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. The company was founded in 1992 and is based in London, the United Kingdom.

AZN Latest News Stream

Event/Time News Detail
Loading, please wait...

AZN Latest Social Stream

Loading social stream, please wait...

View Full AZN Social Stream

Latest AZN News From Around the Web

Below are the latest news stories about ASTRAZENECA PLC that investors may wish to consider to help them evaluate AZN as an investment opportunity.

New COVID vaccine rollout running into insurance, supply roadblocks

The rollout of new COVID-19 vaccines is being obstructed by insurance and supply roadblocks, as customers experience issues with getting insurers to agree on vaccine coverage. The Department of Health and Human Services wrote a letter to insurers stating, "Your obligation as a plan or issuer to ensure that your members have coverage for COVID-19 vaccines without cost sharing is not conditional upon parties' compliance." Yahoo Finance Health Care Reporter Anjalee Khemlani breaks down the news. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.

Yahoo | September 25, 2023

FDA Expands Lilly (LLY) Jardiance Label in Chronic Kidney Disease

Following the latest approval, Lilly's (LLY) Jardiance can access a target market that affects more than 35 million adults in the United States.

Yahoo | September 25, 2023

AstraZeneca's (AZN) Dato-DXd Meets Goal in Breast Cancer Study

AstraZeneca (AZN) announces positive results from the late-stage study evaluating its antibody-drug conjugate, Dato-DXd, in pre-treated patients with HR+/HER2- metastatic breast cancer.

Yahoo | September 25, 2023

AstraZeneca stock upgraded to Buy at Jefferies

Shares of biopharmaceutical giant AstraZeneca (AZN) were upgraded to "Buy" from "Hold" at Jefferies. The analyst says assets outside of the company's oncology pipeline are being overlooked. Yahoo Finance breaks down the stock's reaction. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.

Yahoo | September 25, 2023

CDC Recommends Pfizer's (PFE) RSV Jab to Protect Newborns

Pfizer's (PFE) Abrysvo has been recommended by the CDC for preventing RSV in infants by immunizing pregnant women, during weeks 32-36 of pregnancy.

Yahoo | September 25, 2023

Read More 'AZN' Stories Here

AZN Price Returns

1-mo -1.19%
3-mo -3.66%
6-mo -1.66%
1-year 30.03%
3-year 31.04%
5-year 95.15%
YTD 2.10%
2022 19.10%
2021 19.66%
2020 3.06%
2019 35.58%
2018 13.77%

AZN Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full AZN Dividend History

Continue Researching AZN

Here are a few links from around the web to help you further your research on Astrazeneca Plc's stock as an investment opportunity:

Astrazeneca Plc (AZN) Stock Price | Nasdaq
Astrazeneca Plc (AZN) Stock Quote, History and News - Yahoo Finance
Astrazeneca Plc (AZN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!